🇺🇸 FDA
Patent

US 11839604

Use of sublingual dexmedetomidine for the treatment of agitation

granted A61KA61K31/4174A61K45/06

Quick answer

US patent 11839604 (Use of sublingual dexmedetomidine for the treatment of agitation) held by BioXcel Therapeutics, Inc. expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioXcel Therapeutics, Inc.
Grant date
Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/4174, A61K45/06, A61K47/10, A61K9/006